Top

Published in:

01-03-2020 | Sarcopenia | Original Research

Psychometric Properties of the Spanish Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia

Authors: Raquel Fábrega-Cuadros, Antonio Martínez-Amat, David Cruz-Díaz, Agustín Aibar-Almazán, Fidel Hita-Contreras

Published in: Calcified Tissue International | Issue 3/2020

Abstract

The Sarcopenia and Quality of Life questionnaire (SarQol®) is a self-administered multidimensional sarcopenia-specific tool designed for community-dwelling subjects aged 65 years and older. The purpose of the present study was to evaluate the psychometric properties of the Spanish version of the SarQoL®. A total of 252 participants aged ≥ 65 years voluntarily participated in this cross-sectional study. Handgrip strength and bioelectrical impedance analysis were used for sarcopenia screening. Discriminative power, internal consistency, test–retest reliability, and floor and ceiling effects were analyzed. The generic 36-item Short-Form Health Survey (SF-36), the European Quality of Life 5-Dimension-3 Level (EQ-5D-3L), and the Hospital Anxiety and Depression Scale (HADS) were also used for convergent and divergent validity. Significant differences between sarcopenic (n = 66) and non-sarcopenic participants were observed for SarQoL® total score (p = 0.008) and for all domains except D2—locomotion. A high internal consistency of SarQoL® total score (Cronbach’s alpha = 0.904) was found, and significant domain-to-total score correlations were obtained (all p < .001). Test–retest data showed excellent reliability for SarQoL® total score (ICC = 0.99; 95%CI 0.98–0.99) and in all dimensions, except for D6—leisure and D7—fears activities (substantial). No floor and ceiling effects were observed for SarQoL® total score. SarQoL® total score showed good and acceptable correlations(p < 0.001) with the selected domains of the SF-36 and EQ-5D-3L which have similar dimensions (convergent validity). Low and non-significant correlations existed with anxiety, depression, and EQ-5D-3L self-care and pain/discomfort domains (divergent validity). The Spanish SarQoL® shows satisfactory general psychometric properties in Spanish-speaking older adults from Spain and is able to discriminate between older adults with and without sarcopenia.

Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero I (2012) Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas 71(2):109–114. https://doi.org/10.1016/j.maturitas.2011.11.012 CrossRefPubMed

Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127(5):990S–991S. https://doi.org/10.1016/j.cger.2011.03.003 CrossRefPubMed

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423. https://doi.org/10.1093/ageing/afq034 CrossRef

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31. https://doi.org/10.1093/ageing/afy169 CrossRef

Schaap LA, van Schoor NM, Lips P, Visser M (2018) Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A 73(9):1199–1204. https://doi.org/10.1093/gerona/glx245 CrossRef

Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE (2016) SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 7(1):28–36. https://doi.org/10.1002/jcsm.12048 CrossRefPubMed

Chang KV, Hsu TH, Wu WT, Huang KC, Han DS (2016) Association between sarcopenia and cognitive impairment: a systematic review and meta-analysis. J Am Med Dir Assoc 17(12):1164.e7–64.e15. https://doi.org/10.1016/j.jamda.2016.09.013 CrossRef

Bahat G, Ilhan B (2016) Sarcopenia and the cardiometabolic syndrome: a narrative review. Eur Geriatr Med 6:220–223. https://doi.org/10.1016/j.eurger.2015.12.012 CrossRef

De Buyser SL, Petrovic M, Taes YE, Toye KR, Kaufman JM, Lapauw B, Goemaere S (2016) Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing 45(5):602–608. https://doi.org/10.1093/ageing/afw071 CrossRefPubMed

10.

Beaudart C, Reginster JY, Petermans J, Gillain S, Quabron A, Locquet M, Slomian J, Buckinx F, Bruyère O (2015) Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Exp Gerontol 69:103–110. https://doi.org/10.1016/j.exger.2015.05.003 CrossRefPubMed

11.

Sun S, Lee H, Yim HW, Won HS, Ko YH (2019) The impact of sarcopenia on health-related quality of life in elderly people: Korean National Health and Nutrition Examination Survey. Korean J Intern Med 34(4):877–884. https://doi.org/10.3904/kjim.2017.182 CrossRefPubMed

12.

Tsekoura M, Kastrinis A, Katsoulaki M, Billis E, Gliatis J (2017) Sarcopenia and Its Impact on Quality of Life. Adv Exp Med Biol 987:213–218. https://doi.org/10.1007/978-3-319-57379-3_19 CrossRefPubMed

13.

Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, Petermans J, Gillain S, Buckinx F, Van Beveren J, Jacquemain M, Italiano P, Dardenne N, Bruyere O (2015) Development of a self-administered quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing 44(6):960–966. https://doi.org/10.1093/ageing/afv133 CrossRefPubMedPubMedCentral

14.

Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, Petermans J, Gillain S, Buckinx F, Dardenne N, Bruyère O (2017) Validation of the SarQoL(R), a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 8(2):238–244. https://doi.org/10.1002/jcsm.12149 CrossRefPubMed

15.

Beaudart C, Edwards M, Moss C, Reginster JY, Moon R, Parsons C, Demoulin C, Rizzoli R, Biver E, Dennison E, Bruyere O, Cooper C (2017) English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age Ageing 46(2):271–276. https://doi.org/10.1093/ageing/afw192 CrossRefPubMed

16.

Gasparik AI, Mihai G, Beaudart C, Bruyere O, Pop RM, Reginster JY, Pascanu IM (2017) Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Arch Osteoporos 12(1):103. https://doi.org/10.1007/s11657-017-0397-1 CrossRefPubMed

17.

Hodinka L, Vereckei E, Gasparik AI (2018) Sarcopenia and quality of life: the validated Hungarian translation of the Sarcopenia Quality of Life (SarQoL) questionnaire. Orv Hetil 159(36):1483–1486. https://doi.org/10.1556/650.2018.31157 CrossRefPubMed

18.

Konstantynowicz J, Abramowicz P, Glinkowski W, Taranta E, Marcinowicz L, Dymitrowicz M, Reginster JY, Bruyere O, Beaudart C (2018) Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. J Clin Med 7(10):pii: E323. https://doi.org/10.3390/jcm7100323 CrossRefPubMedCentral

19.

Tsekoura M, Billis E, Gliatis J, Tsepis E, Matzaroglou C, Sakkas GK, Beaudart C, Bruyere O, Tyllianakis M, Panagiotopoulos E (2018) Cross cultural adaptation of the Greek sarcopenia quality of life (SarQoL) questionnaire. Disabil Rehabil 19:1–7. https://doi.org/10.1080/09638288.2018.1514076 CrossRef

20.

Geerinck A, Scheppers A, Beaudart C, Bruyère O, Vandenbussche W, Bautmans R, Delye S, Bautmans I (2018) Translation and validation of the Dutch SarQoL®, a quality of life questionnaire specific to sarcopenia. J Musculoskelet Neuronal Interact 18(4):463–472PubMedPubMedCentral

21.

United Nations. World Population Prospects: The 2006 Revision 2008.

22.

Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012 CrossRefPubMed

23.

World Health Organization. Obesity: Preventing and Management of the Global Epidemic. Report of the WHO Consultation. Technical Report Series, No. 894. Geneva, Switzerland: World Health Organization, 2000.

24.

Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris J, Paffenbarger RS, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH (1995) Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273(5):402–407. https://doi.org/10.1001/jama.273.5.402 CrossRefPubMed

25.

Janssen I, Heymsfield SB, Baumgartner RN, Ross R (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 89(2):465–471. https://doi.org/10.1152/jappl.2000.89.2.465 CrossRefPubMed

26.

Chien Y, Huang TY, Wu YT (2008) Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 56(9):1710–1715. https://doi.org/10.1111/j.1532-5415.2008.01854.x CrossRefPubMed

27.

Beaudart C, Rolland Y, Cruz-Jentoft AJ, Bauer JM, Sieber C, Cooper C, Al-Daghri N, Araujo de Carvalho I, Bautmans I, Bernabei R, Bruyère O, Cesari M, Cherubini A, Dawson-Hughes B, Kanis JA, Kaufman JM, Landi F, Maggi S, McCloskey E, Petermans J, Rodriguez Mañas L, Reginster JY, Roller-Wirnsberger R, Schaap LA, Uebelhart D, Rizzoli R, Fielding RA (2016) Assessment of Muscle Function and Physical Performance in Daily Clinical Practice : A position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Calcif Tissue Int 105(1):1–14. https://doi.org/10.1007/s00223-019-00545-w CrossRef

28.

Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, Der G, Gale CR, Inskip HM, Jagger C, Kirkwood TB, Lawlor DA, Robinson SM, Starr JM, Steptoe A, Tilling K, Kuh D, Cooper C, Sayer AA (2014) Grip strength across the life course: normative data from twelve British studies. PLoS ONE 9(12):e113637. https://doi.org/10.1371/journal.pone.0113637 CrossRefPubMedPubMedCentral

29.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item Short-Form Health Survey (SF-36). I conceptual framework and item selection. Med Care 30(6):473–483.

30.

Alonso J, Prieto L, Anto JM (1995) The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 104(20):771–776

31.

The EuroQol Group (1990) EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208. https://doi.org/10.1016/0168-8510(90)90421-9 CrossRef

32.

Badia X, Roset M, Montserrat S, Herdman M, Segura A (1999) The Spanish version of EuroQol: A description and its applications. European Quality of Life scale. Med Clin (Barc) 112(Suppl1):79–85.

33.

Zigmond AS, Snaith PR (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x CrossRefPubMed

34.

Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A (2003) A validation study of the Hospital Anxiety and Depression Scale (HADS) in a Spanish population. Gen Hosp Psychiatry 25(4):277–283. https://doi.org/10.1016/S0163-8343(03)00043-4 CrossRefPubMed

35.

Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428CrossRefPubMed

36.

Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142S–158S.CrossRef

37.

Nunnally JC BI (1994) Psychometric theory New York: McGrawHill Inc.

38.

Hays RD, Morales LS, Reise SP (2000) Item response theory and health outcomes measurement in the 21st century. Med Care 38(9Suppl):II28–42.CrossRef

39.

Kim KE, Jang SN, Lim S, Park YJ, Paik NJ, Kim KW, Jang HC, Lim JY (2012) Relationship between muscle mass and physical performance: Is it the same in older adults with weak muscle strength? Age Ageing 41(6):799–803. https://doi.org/10.1093/ageing/afs115 CrossRefPubMed

40.

Kim YH, Kim KI, Paik NJ, Kim KW, Jang HC, Lim JY (2016) Muscle strength: A better index of low physical performance than muscle mass in older adults. Geriatr Gerontol Int 16(5):577–585. https://doi.org/10.1111/ggi.12514 CrossRefPubMed

41.

Pisciottano MV, Pinto SS, Szejnfeld VL, Castro CH (2014) The relationship between lean mass, muscle strength and physical ability in independent healthy elderly women from the community. J Nutr Health Aging 18(5):554–558CrossRefPubMed

42.

Geerinck A, Bruyère O, Locquet M, Reginster JY, Beaudart C (2018) Evaluation of the Responsiveness of the SarQoL® Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia. Adv Ther 35(11):1842–1858. https://doi.org/10.1007/s12325-018-0820-z CrossRefPubMedPubMedCentral

43.

Sánchez-Rodríguez D, Marco E, Dávalos-Yerovi V, López-Escobar J, Messaggi-Sartor M, Barrera C, Ronquillo-Moreno N, Vázquez-Ibar O, Calle A, Inzitari M, Piotrowicz K, Duran X, Escalada F, Muniesa JM, Duarte E (2019) Translation and Validation of the Spanish Version of the SARC-F Questionnaire to Assess Sarcopenia in Older People. J Nutr Health Aging 23(6):518–524. https://doi.org/10.1007/s12603-019-1204-z CrossRefPubMed

Title: Psychometric Properties of the Spanish Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia
Authors: Raquel Fábrega-Cuadros
Antonio Martínez-Amat
David Cruz-Díaz
Agustín Aibar-Almazán
Fidel Hita-Contreras
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Sarcopenia
Anxiety
Published in: Calcified Tissue International / Issue 3/2020
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-019-00635-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Relationship of COL9A1 and SOX9 Genes with Genetic Susceptibility of Postmenopausal Osteoporosis

Associations Between Breastfeeding History and Early Postmenopausal Bone Loss

Hypophosphatasia in Japan: ALPL Mutation Analysis in 98 Unrelated Patients

Associations of Iron Intake, Serum Iron and Serum Ferritin with Bone Mineral Density in Women: The National Health and Nutrition Examination Survey, 2005–2010

Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study

Loss of Lgals3 Protects Against Gonadectomy-Induced Cortical Bone Loss in Mice

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage